KruegerJ.G.The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol.2002; 46: 1–23.
9.
National Psoriasis Foundation Web site.
10.
The Healthcare Sales and Marketing Network.
11.
ChewA.L., BennettA., SmithC.H., BarkerJ., KirkhamB.Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. Br J Dermatol2004; 151: 492–6.
12.
YoudimA., VasiliauskasE.A., TarganS.R., PapadakisK.A., IppolitiA., DubinskyM.C., LechagoJ., PaavolaJ., LoaneJ., LeeS.K., GaiennieJ., SmithK., DoJ., AbreuM.T.A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis2004 Jul; 10(4): 333–8.
13.
den BroederA., van de PutteL., RauR., SchattenkirchnerM., Van RielP., SanderO., BinderC., FennerH., BankmannY., VelagapudiR., KempeniJ., KupperH.A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J Rheumatol2002 Nov; 29(11): 2288–98.
14.
MorelandL.W.Drugs that block tumour necrosis factor: experience in patients with rheumatoid arthritis. Pharmacoeconomics2004; 22(2 Suppl): 39–53.
15.
BangL.M., KeatingG.M.Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs2004; 18(2): 121–39.
16.
KeystoneE.C., KavanaughA.F., SharpJ.T., TannenbaumH., HuaY., TeohL.S., FischkoffS.A., ChartashE.K.Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum2004 May; 50(5): 1400–11.
17.
HanauerS., LukasM., MacintoshD., RutgeertsP., SandbornW., PollackP.A randomized, double-blind, placebo-controlled trial of the human anti-TNF-alpha monoclonal antibody adalimumab for the induction of remission in patients with moderate to severely active Crohn's disease. Gastroenterology2004; 127: 332.
18.
ScheinfeldN.Adalimumab (HUMIRA): a review. J Drugs Dermatol2003; 2: 375–7.
19.
MackayF., SierroF., GreyS.T., GordonT.P.The BAFF/APRIL system: an important player in systemic rheumatic diseases. Curr Dir Autoimmun2005; 8: 243–65.
20.
ZhangY., HolfordT.R., LeadererB., ZahmS.H., BoyleP., MortonL.M., ZhangB., ZouK., FlynnS., TalliniG., OwensP.H., ZhengT.Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control2004 May; 15(4): 419–28.
21.
No authors listed. Adalimumab: new preparation. Rheumatoid arthritis: no therapeutic advance. Prescrire Int2004 Oct; 13(73): 171–5.
22.
EmeryP.Role of adalimumab, a novel TNF antagonist in advancing rheumatoid arthritis control. Drugs Today (Barc)2003; 39 Suppl B: 17–23.
23.
BansbackN., BrennanA., GhatnekarO.The cost effectiveness of adalimumab in the treatment of moderate to severe rheumatoid arthritis patients in Sweden. Ann Rheum Dis2004 Nov 18; [Epub ahead of print]
24.
GelfandJ.M., FeldmanS.R., SternR.S., ThomasJ., RolstadT., MargolisD.J.Determinants of quality of life in patients with psoriasis: a study from the U.S. population. J Am Acad Dermatol2004 Nov; 51(5): 704–8.
